Last reviewed · How we verify
Etavopivat Tablets Low dose
Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.
Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells. Used for Sickle cell disease.
At a glance
| Generic name | Etavopivat Tablets Low dose |
|---|---|
| Also known as | FT-4202 |
| Sponsor | Forma Therapeutics, Inc. |
| Drug class | KCNQ1 potassium channel activator |
| Target | KCNQ1 |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Etavopivat is a KCNQ1 potassium channel activator that promotes the differentiation of erythroid progenitor cells toward fetal hemoglobin-producing cells. By increasing HbF levels, the drug reduces sickling and hemolysis in patients with sickle cell disease, thereby reducing vaso-occlusive crises and other complications associated with the disease.
Approved indications
- Sickle cell disease
Common side effects
- Abdominal pain
- Nausea
- Diarrhea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etavopivat Tablets Low dose CI brief — competitive landscape report
- Etavopivat Tablets Low dose updates RSS · CI watch RSS
- Forma Therapeutics, Inc. portfolio CI